Zydus Wellness logo

Zydus Wellness

ZYDUSWELL NSE

Key Fundamentals

SmallcapPackaged FoodsFood Products
Market Cap
₹17,726 Cr
Volatility
Moderate
P/E Ratio
93.24
EBITDA
₹516 Cr
Return on Equity
3.38%
Debt to Equity
0.55
Book Value
₹183.12
EPS
₹47.81
52W High
₹611.85
52W Low
₹367.55

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

4
  • Stock is trading at 3.01 times its book value
  • Company has a low return on equity of 5.08% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 14.1% of profits over last 3 years

Growth Rate

Revenue Growth
45.73% higher than 3Y
Net Income Growth
-43.15% lower than 3Y
Cash Flow Change
-40.42% lower than 3Y
ROE
-44.77% lower than 3Y
ROCE
-47.31% lower than 3Y
EBITDA Margin (Avg.)
-9.97% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk high

Zydus Wellness Ltd trades at a market cap of ₹17,726 Cr with a PE of 95.5x, reflecting premium valuation. The company has delivered strong TTM sales growth of 66% but TTM profit has declined 31%, while 3-year average ROE remains low at 5%. The stock presents a mix of accelerating topline momentum against compressed profitability and expensive valuation multiples.

Bull Case 7
  • TTM revenue growth of 66% is exceptionally strong, significantly ahead of the 3-year sales CAGR of 21% and 5-year CAGR of 16%, indicating sharp topline acceleration
  • 10-year compounded sales CAGR of 26% demonstrates a long track record of consistent revenue expansion in the FMCG/food products space
  • 5-year sales CAGR of 16% comfortably outpaces many peers in the food products sector, reflecting structural demand for its brand portfolio
  • Company is expected to deliver a good upcoming quarter, which could serve as a near-term catalyst for re-rating
  • 10-year compounded profit CAGR of 8% shows the company has historically been able to grow earnings over longer cycles despite near-term pressure
  • 1-year stock price return of 11% and 3-year CAGR of 20% indicate sustained investor confidence and positive price momentum
  • Price-to-book ratio of 3.09x, while above book value, is not extreme for an FMCG company with established consumer brands, suggesting some asset-backed support
Bear Case 8
  • PE ratio of 95.5x is extremely elevated, pricing in significant future growth that may not materialize given declining profits — TTM profit declined 31%
  • 3-year compounded profit CAGR of -10% and 5-year profit CAGR of -2% show a sustained and worsening trend of earnings deterioration
  • 3-year average ROE of just 5% (last year only 4%) is very low for an FMCG company, indicating poor capital efficiency and weak shareholder returns
  • Dividend payout of only 14.1% of profits over the last 3 years is low, and the current dividend yield of 0.21% offers negligible income to shareholders
  • Company may be capitalizing interest costs, which could overstate reported profits and understate the true debt servicing burden on operations
  • 5-year stock CAGR of only 3% despite 16% sales CAGR over the same period suggests the market has already been skeptical about translating revenue into value creation
  • Widening gap between strong topline growth (66% TTM sales) and declining profitability (-31% TTM profit) raises concerns about margin compression, rising input costs, or heavy promotional spending
  • 5-year and 10-year ROE averaging only 6% indicates this is a structural issue rather than a temporary cyclical downturn

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Headwinds 1
  • Acquisition-driven debt surge Sep 2

    Comfort Click acquisition pushed debt to ₹30,711 million, weighing on net profit despite strong top-line growth in FY26.

Positives 3
  • ESG score improves to 71.7 Sep 3

    SES ESG Research upgraded Zydus Wellness ESG score from 70 to 71.7 in FY25, disclosed under SEBI Listing Regulations on September 3, 2026.

  • Revenue surges 46% in FY26 Sep 2

    Zydus Wellness reported 46% revenue growth to ₹36,610 million in FY26, driven by the Comfort Click acquisition.

  • Experienced CRO appointed Sep 1

    Kapil Sharma appointed as CRO for India and Indian subcontinent effective September 1, 2026, bringing 28+ years of experience including 25 years at P&G.

Neutral 1
  • Promoter share transmission Aug 24

    27,250 equity shares transmitted to Prashant Babubhai Patel from the estate of Late Jasodaben Babubhai Patel via off-market transaction under SEBI PIT Regulations.

TL;DR: Zydus Wellness delivered strong 46% revenue growth in FY26 to ₹36,610 million, fueled by the Comfort Click acquisition, and strengthened leadership with a seasoned CRO hire. However, acquisition-related debt of ₹30,711 million is pressuring profitability. ESG credentials are improving incrementally. The key forward question is whether revenue momentum can translate into deleveraging and net profit recovery over the next few quarters.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
702
440
403
783
841
493
462
913
861
650
965
1,485
1,437
Expenses
586
423
390
620
686
473
447
723
705
628
904
1,215
1,195
Operating Profit
116
17
13
162
155
20
15
190
156
23
61
270
242
OPM %
17%
3.8%
3.1%
21%
18%
4%
3.2%
21%
18%
3.5%
6%
18%
17%
Other Income
-12
4
3
4
5
10
4
1
3
-33
-6
1
4
Interest
5
6
6
6
4
1
3
4
2
16
41
39
26
Depreciation
6
6
6
6
5
5
5
13
11
25
56
55
57
PBT
93
9
4
154
152
24
10
173
145
-51
-42
177
162
Tax %
-18%
31%
92%
3%
3%
12%
37%
1%
12%
4%
-4%
9%
27%
Net Profit
110
6
0
150
148
21
6
172
128
-53
-40
162
119
EPS in Rs
3.47
0.19
0.01
4.72
4.64
0.66
0.2
5.4
4.02
-1.66
-1.25
5.09
3.74
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
431
397
431
513
843
1,767
1,867
2,009
2,255
2,328
2,709
3,961
4,537
Expenses
331
305
331
387
658
1,446
1,522
1,664
1,918
2,020
2,329
3,451
3,941
Operating Profit
100
91
99
125
185
321
344
345
337
308
380
510
596
OPM %
23%
23%
23%
24%
22%
18%
18%
17%
15%
13%
14%
13%
13%
Other Income
28
32
32
35
28
-33
-123
10
-5
0
20
-34
-34
Interest
0
0
1
2
30
140
84
26
16
24
12
98
122
Depreciation
8
7
7
9
13
26
25
24
25
24
28
147
193
PBT
120
117
124
150
171
121
112
306
291
260
359
230
247
Tax %
7%
10%
10%
9%
0%
-17%
-6%
-1%
-7%
-3%
3%
14%
—
Net Profit
111
105
111
137
171
142
119
309
310
267
347
197
188
EPS in Rs
5.58
5.28
5.58
6.85
5.87
4.92
3.73
9.71
9.75
8.39
10.9
6.2
5.92
Div. Payout %
22%
25%
23%
23%
17%
20%
27%
10%
10%
12%
11%
19%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
39
39
39
39
58
58
64
64
64
64
64
64
Reserves
367
439
518
652
3,329
3,403
4,504
4,780
5,059
5,294
5,608
5,762
Borrowings
0
0
25
25
1,569
1,519
550
387
297
329
188
3,203
Other Liabilities
102
89
100
112
503
610
548
461
413
462
582
1,161
Total Liabilities
508
568
682
829
5,459
5,590
5,666
5,692
5,833
6,148
6,442
10,190
Fixed Assets
84
82
103
104
4,567
4,674
4,667
4,710
4,732
4,708
5,125
8,596
CWIP
0
0
0
0
10
4
4
12
13
10
15
23
Investments
0
94
30
148
46
110
0
27
70
78
36
5
Other Assets
423
391
550
577
835
802
995
943
1,018
1,354
1,266
1,566
Total Assets
508
568
682
829
5,459
5,590
5,666
5,692
5,833
6,148
6,442
10,190
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
69
90
77
69
149
259
287
237
92
246
380
226
Investing
29
-28
-72
-59
-4,092
-17
-10
-59
-85
-178
-207
-2,881
Financing
-27
-58
-6
-2
4,052
-260
-216
-234
-138
-26
-186
2,698
Net Cash Flow
71
4
-1
8
109
-18
60
-56
-132
43
-13
44
Free Cash Flow
72
86
46
61
132
235
269
162
47
220
315
126
CFO/OP
80
114
86
64
115
81
83
70
28
81
99
50
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
1
3
3
6
42
24
18
26
34
44
49
35
Inventory Days
76
73
127
113
393
168
158
135
146
150
148
178
Days Payable
146
191
264
254
662
289
189
136
100
116
122
107
Cash Conversion Cycle
-69
-116
-134
-135
-227
-97
-13
25
80
78
75
106
Working Capital Days
-37
-38
-57
-26
-26
-7
-35
-27
17
20
34
48
ROCE %
32%
26%
23%
22%
7%
6%
6%
6%
6%
5%
6%
5%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zydus Wellness insights

69 extracted metrics + investor summaries across FY09–FY27.

Log in — free

Shareholding Pattern

Others1.76%Promot.69.64%FIIs3.32%Public6.15%DIIs19.14%As ofJun 2026

Documents

Frequently Asked Questions about Zydus Wellness

What does Zydus Wellness Ltd do?
Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.(Sou...
Where is Zydus Wellness Ltd (ZYDUSWELL) listed?
Zydus Wellness Ltd trades as ZYDUSWELL on the NSE and under code 531335 on the BSE.
Which sector does Zydus Wellness Ltd belong to?
Zydus Wellness Ltd is classified under the Food Products sector, in the Packaged Foods industry.
What is the market capitalisation of Zydus Wellness Ltd?
Zydus Wellness Ltd has a market capitalisation of ₹17,726 Cr, which places it in the Mid Cap band.
What is the PE ratio of Zydus Wellness Ltd?
Zydus Wellness Ltd trades at a PE ratio of 93.24, on earnings per share of ₹47.81, against a book value of ₹183.12 per share.
What is the 52-week high and low of Zydus Wellness Ltd?
Over the last 52 weeks Zydus Wellness Ltd has traded between ₹367.55 and ₹611.85.
Does Zydus Wellness Ltd pay dividends?
Zydus Wellness Ltd has a dividend yield of 0.21%.
What is the Return on Equity (ROE) of Zydus Wellness Ltd?
Zydus Wellness Ltd reported a return on equity of 3.38%. Its debt-to-equity ratio is 0.55.

Company Information

Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.(Source : 202003 Annual Report Page No: 83)

Website zyduswellness.in
CEO Mr. Tarun G. Arora
Employees 1,247
Listed 2009-11-13
Face Value ₹ 2
Issued Size 31,81,60,720

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZYDUSWELL.md for Zydus Wellness Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Food Products → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List